Celldex Reports $121K Revenue Miss, -$1.22 EPS and 13.01 Current Ratio
Celldex Therapeutics reported Q4 EPS of -$1.22, missing the -$1.01 estimate and generating $121,000 in revenue versus the $1.39 M forecast. The biotech’s rich valuation (P/S 296.3, EV/S 188.1) contrasts its liquidity strength (current ratio 13.01) and minimal debt (D/E 0.0044).
1. Q4 Financial Results
Celldex reported EPS of -$1.22 for the quarter, missing the estimated -$1.01, and posted revenue of $121,000 versus the forecasted $1.39 million, highlighting ongoing financial challenges.
2. Valuation Metrics
The company’s price-to-sales ratio stands at 296.3 and EV/Sales at 188.14, while the negative P/E of -9.12 and earnings yield of -10.97% reflect its unprofitable operations.
3. Clinical Trial Progress
Celldex has fully enrolled its Phase 3 study for chronic spontaneous urticaria, with topline data expected in Q4 2026, and is actively enrolling patients in Phase 3 trials for cold urticaria and symptomatic dermographism.
4. Liquidity and Debt Position
A current ratio of 13.01 indicates strong short-term liquidity, and a debt-to-equity ratio of 0.0044 shows the company’s minimal reliance on debt financing.